Antimicrobial resistance kills more than a million people every year and the pipeline of new antibiotics is nearly empty. Wockhardt Limited, founded in Mumbai in 1967, is the only pharmaceutical company in the world to hold Qualified Infectious Disease Product status from the US FDA for six novel antibiotics. In an industry where most companies have abandoned antibiotic development because the economics don’t work, Wockhardt stayed.
The world is running out of effective antibiotics. Drug-resistant bacteria — superbugs — are evolving faster than new treatments are being developed, and most pharmaceutical companies have exited antibiotic research because the return on investment cannot compete with oncology or immunology. The few new antibiotics that do reach patients are typically repurposed from existing chemical classes, offering incremental improvement rather than genuine novelty.
Wockhardt approached this problem differently. Over more than a decade of research, the company developed six new chemical entities — genuinely novel molecules, not reformulations of existing drugs — each targeting resistant gram-positive or gram-negative bacteria. The US FDA granted all six Qualified Infectious Disease Product status, a designation that provides fast-track review and market exclusivity. No other company in the world holds QIDP status for six compounds.
The flagship is ZAYNICH (WCK 5222), a novel antibiotic combination targeting multi-drug-resistant gram-negative infections. In compassionate-use cases, it achieved 100% clinical success. EMROK, launched in India in FY 2021, made Wockhardt the first Indian pharmaceutical company to commercialise a new chemical entity in the anti-infective space.
Wockhardt’s path to its current identity was not linear. In the early 2010s, the company was a mid-sized generics manufacturer with significant US operations. Regulatory challenges with US FDA inspections disrupted those operations and forced a strategic rethink. Revenue, which had peaked near $600 million, contracted. The US business shrank from a quarter of revenue to single digits in some years.
Rather than simply rebuilding the generics pipeline, Wockhardt made a consequential choice: it would transform from a generics-first company into an innovation-led enterprise focused on the one area of medicine where the need was most urgent and most ignored. Antibiotic research consumed 15% of revenue in some years — a level of R&D intensity that is unusual even among companies ten times Wockhardt’s size.
The cost of this bet is visible in the revenue trajectory: $538 million in FY 2015, $369 million in FY 2025. But the EBITDA story is different — operating profit grew 67% year-over-year in FY 2025, reflecting a leaner organisation focused on higher-value activities. The company that once competed on volume now competes on molecules that no one else has.
While the US business contracted, Wockhardt’s European operations became its centre of gravity. In FY 2025, the EU & UK accounted for 51% of revenue, making Wockhardt one of the most Europe-dependent Indian pharmaceutical companies. The UK alone, where Wockhardt operates manufacturing facilities in Wrexham, North Wales, anchors the regional business. The company ranks among the top three Indian generic companies in the UK.
India contributes 22% of revenue, with a focus on branded generics in diabetes, anti-infectives, and vitamins. The rest-of-world segment — spanning the Middle East, Southeast Asia, Africa, and Latin America — accounts for 24%, and represents the fastest-growing part of the portfolio as Wockhardt expands its novel antibiotic franchise into markets where antimicrobial resistance is most acute.
Wockhardt operates in more than 45 countries with manufacturing facilities in India, the United Kingdom, and Ireland. The company’s geographic mix has shifted dramatically over the past decade — from a US-centric model to one anchored in Europe and emerging markets, reflecting both the regulatory challenges in the US and the strategic pivot toward markets where Wockhardt’s novel antibiotics address the most urgent unmet needs.
All six hold QIDP status from the US FDA
Wockhardt operates manufacturing facilities in India, the United Kingdom, and Ireland, with two US FDA-registered sites. The company’s R&D centres in India, the UK, and the US hold 82 US FDA drug approvals (all ANDAs) and 133 Indian Patent Office grants. Beyond pharmaceuticals, Wockhardt operates in biologicals — manufacturing insulin and insulin analogues — and has capabilities in vaccine production, including a manufacturing partnership for COVID-19 vaccines during the pandemic.
Sources: Wockhardt Annual Reports FY2014–15 through FY2024–25. US FDA facility registration data. US FDA QIDP designation records. Indian patent office records.